Evaluation of dry eye and meibomian gland dysfunction with meibography in patients with lamellar ichthyosis
Session Details
Session Title: Quality of Vision and Dry Eye
Session Date/Time: Sunday 08/10/2017 | 08:00-09:30
Paper Time: 08:00
Venue: Room 3.4
First Author: : I.Karaca TURKEY
Co Author(s): : M. Palamar H. Onay I. Ertam A. Yagci
Abstract Details
Purpose:
To evaluate the dry eye tests and meibography of patients with lamellar ichthyosis.
Setting:
Ege University, Department of Ophthalmology, Izmir-TURKEY
Methods:
Twenty-four eyes of 12 patients with lamellar ichthyosis (Group 1) and twenty-four eyes of 12 healthy individuals (Group 2) were enrolled. Comprehensive eye examination along with corneal and conjunctival fluorescein staining and Oxford scoring, tear film break-up time, Schirmer 1 test, ocular surface disease index (OSDI) score assessment, and evaluation of upper and lower eyelid Meibomian glands using infrared filter of slit-lamp biomicroscope (SL-D701 with DC-4 digital camera and BG-5 background illuminator, TOPCON, Tokyo, Japan) were performed (from grade 0 (no loss of Meibomian glands) to grade 3 (gland dropout >2/3 of the total Meibomian glands).
Results:
The mean ages of Group 1 and Group 2 were 25.3±15.6 (range, 9-61) and 25.3±13.3 (range, 9-52), respectively (p=0.997). No significant difference in best-corrected visual acuity, Schirmer 1 test and Oxford scale scores were detected in between groups. In Group 1, mean tear film break-up time was lower (p=0.013), OSDI score, lower, upper and total (upper + lower) meiboscores were significantly higher as compared with Group 2 (p=0.000, p=0.001, p=0.001, p=0.001, respectively).
Conclusions:
As demonstrated by this study lamellar ichthyosis is associated with evaporative type dry eye disease with decreased tear film break-up time, normal Schirmer 1 values and Meibomian gland dysfunction that can objectively be demonstrated with meibography. For this reason, in order to prevent undesired complications, these patients should be examined and treated for dry eye disease especially targeting Meibomian gland dysfunction.
Financial Disclosure:
NONE